A follow-up study of the RESONATE phase III trial provides further support that ibrutinib, an inhibitor of Bruton tyrosine kinase, achieves greater PFS than ofatumumab, a high OS rate, and high tolerability among patients with CLL who have had at least one prior treatment.
Dr. Maura L. Gillison, who presented the findings, also presented a minimum 11.4-month follow-up analysis of CheckMate 141 for the overall patient population in the study to update the previous 2.2-month follow-up findings.
The results of a global phase III trial, suggest that alectinib, an ALK tyrosine-kinase inhibitor, leads to greater PFS and longer duration until CNS progression in patients with untreated, advanced ALK-positive non–small cell lung cancer compared with crizotinib.
A meta-analysis of three randomized clinical trials fails to support use of selective internal radiotherapy in combination with first-line oxaliplatin and fluorouracil chemotherapy in patients with liver-only and liver-dominant metastatic colorectal cancer.
Results of the large Italian TOSCA trial narrowly failed to meet the primary endpoint but still offer great value to patients with high-risk stage II or stage III colon cancer slated to receive oxaliplatin-based treatment after surgery.
A large trial found that 3 months of adjuvant chemotherapy was noninferior to 6 months for patients with high-risk stage II or stage III colon or rectal cancer. This finding was true for the CAPOX regimen but not for FOLFOX.
The EGFR tyrosine-kinase inhibitor gefitinib appears to offer a disease-free survival benefit over vinorelbine/cisplatin as adjuvant therapy in patients with non–small cell lung cancer with EGFR-activating mutation.
Both nivolumab alone and in combination with ipilimumab resulted in a promising disease control rate in patients with relapsing malignant pleural mesothelioma (MPM), according to the results of Abstract LBA8507.
In contrast to more common cancers, some sarcoma subsets are fairly rare and standard treatments have not been established. However, for each sarcoma type discussed, strategies are being developed with the aim of improving outcomes for patients with sarcoma.
Data from two phase II studies, the CheckMate 204 trial and the Anti-PD1 Brain Collaboration trial, lend support to combined use of nivolumab and ipilimumab to yield responses in melanoma that has metastasized to the brain.